Key result
In a patient with bi-atrial thrombus via patent foramen ovale and concurrent pulmonary embolism, Angiovac was considered as a modern procedural treatment option.
Why the study?
Uncommon diagnoses requiring anticoagulation may lack extensively studied treatment plans or clear medical guidelines for successful management.
Case Report (n=1)
Modern procedures like Angiovac should be considered for complex cases of bi-atrial thrombus via PFO with concurrent pulmonary embolism.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for Angiovac in rare bi-atrial thrombus cases; Level 5 evidence leaves open need for prospective validation before any practice consideration.
Numerous diagnoses in the hospital setting require anticoagulation. With different etiologies, certain specific assessments may not have a treatment plan that is studied extensively in evidence-based medical texts. In these uncommon situations, management may not have clear medical guidelines for successful treatment. We present a case of bi-atrial thrombus via PFO with concurrent pulmonary embolism, extensive clot burden history, and the plan to move forward with Angiovac. In patients with this specific history and pathology, modern procedures like Angiovac should be considered and discussed.
No takes yet. Share an insight, caveat, or question.
McCullough et al. (2023) conducted a case report in Bi-atrial thrombus via patent foramen ovale with concurrent pulmonary embolism (n=1). Angiovac was evaluated. In a patient with bi-atrial thrombus via patent foramen ovale and concurrent pulmonary embolism, Angiovac was considered as a modern procedural treatment option.
Synapse has enriched 10 related papers. Consider them for comparative context: